Chembio Diagnostics Announces Approval of Zika, Dengue and Chikungunya Point-of-Care Multiplex Test by Brazil’s...

Tailwinds' Take: continued execution demonstrates their unique ability to create multiplex diagnostics. MEDFORD, N.Y., April 09, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics...

Chembio Diagnostics Announces Agreement with Perseus Science to Advance Point-of-Care Concussion Test

MEDFORD, N.Y., April 02, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the company has...

Chembio Diagnostics Reports Fourth Quarter and Full Year 2018 Financial Results

Tailwinds' Take: a small beat, as expected. Margins low, but due primarily to investing in growth, so like that answer. Longer term targets for...

Chembio Diagnostics Awarded UNICEF Contract to Supply Point-of-Care Zika/Chikungunya/Dengue Tests and Micro Readers

Tailwinds' Take: good news and incremental to their guidance.  MEDFORD, N.Y., March 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today...

Chembio Diagnostics Reports Preliminary Fourth Quarter and Full Year 2018 Revenue

Tailwinds' Take: solid guidance for the Q is well ahead of street forecasts.  MEDFORD, N.Y., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care...

Chembio Diagnostics Announces 2019 Analyst and Investor Meeting

MEDFORD, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will host...

Chembio Diagnostics Receives CE Mark for Point-of-Care Diagnostic Test Developed in Collaboration with...

MEDFORD, N.Y., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has received...

Chembio Diagnostics Announces Pricing of its Public Offering of Common Stock

MEDFORD, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.(NASDAQ: CEMI) (“Chembio”), a provider of point-of-care diagnostic tests for infectious diseases, announced today the pricing of...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.